세계의 급성 골수성 백혈병 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031년)

Persistence Market Research has recently published an in-depth report on the Acute Myeloid Leukemia Treatment Market, providing a comprehensive analysis of key market dynamics such as drivers, trends, opportunities, and challenges. This report delivers exclusive data and insights into the projected growth of the acute myeloid leukemia treatment market from 2024 to 2031.

• Acute Myeloid Leukemia Treatment Market Size (2024E): US$2.4 Bn
• Projected Market Value (2031F): US$4.7 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 10%

Acute Myeloid Leukemia Treatment Market - Report Scope:

Acute Myeloid Leukemia (AML) is an aggressive cancer of the blood and bone marrow, requiring prompt and targeted treatment. The market for AML treatment includes chemotherapy, targeted therapies, immunotherapies, and stem cell transplants. The market's growth is driven by the rising incidence of AML globally, advancements in treatment options, and increased awareness about early diagnosis and treatment.

Market Growth Drivers:

The AML treatment market is primarily driven by an increasing prevalence of the disease, particularly among the aging population. Additionally, the development of novel targeted therapies and immunotherapies is reshaping the landscape of AML treatment, offering improved survival rates and fewer side effects compared to traditional chemotherapy. Government initiatives to promote early diagnosis and clinical trials further contribute to the market's growth. Furthermore, advancements in genetic profiling of AML patients enable personalized treatment approaches, increasing the efficacy of therapies.

Market Restraints:

Despite strong growth potential, the AML treatment market faces several challenges. The high cost of advanced therapies, particularly stem cell transplants and immunotherapies, may limit accessibility, especially in developing regions. Additionally, the complexity of AML as a disease, with multiple genetic mutations involved, poses challenges for effective treatment and necessitates further research and development. The side effects associated with chemotherapy and certain targeted therapies also remain a concern, hindering wider adoption of some treatment options.

Market Opportunities:

The AML treatment market presents significant growth opportunities through advancements in precision medicine and personalized treatment approaches. The rise of next-generation sequencing (NGS) and other diagnostic technologies enables better disease stratification, allowing for more targeted therapies to be developed. Additionally, the integration of artificial intelligence (AI) into drug discovery and treatment planning can optimize therapeutic outcomes. Furthermore, untapped markets in developing regions represent growth potential, especially as healthcare infrastructure improves and access to advanced treatments increases. Strategic collaborations between pharmaceutical companies and research institutions will be key to harnessing these opportunities.

Key Questions Answered in the Report:

• What are the major factors driving the growth of the AML treatment market globally?
• How are new treatment modalities, such as immunotherapies, transforming the AML treatment landscape?
• Which regions are expected to see the highest growth in the AML treatment market, and why?
• Who are the leading players in the AML treatment market, and what strategies are they using to maintain their competitive position?
• What are the latest developments in personalized medicine and genetic profiling for AML?

Competitive Intelligence and Business Strategy:

Key players in the global AML treatment market, including Novartis International AG, Pfizer Inc., and Bristol-Myers Squibb Company, are investing heavily in R&D to introduce innovative therapies. Companies are focusing on expanding their portfolios with novel targeted therapies and partnering with research institutes to develop more effective treatments. In addition, these players are increasingly using strategic mergers and acquisitions to expand their market presence and enhance their drug development pipelines. Patient education and physician training programs are also being emphasized to increase the adoption of new treatment modalities.

Key Companies Profiled:

• Astellas Pharma Inc.
• Bristol Myers Squibb Company
• Celgene Corporation
• Daiichi Sankyo Company, Limited
• Jazz Pharmaceuticals, plc
• Novartis AG
• Otsuka Pharmaceuticals Co., Ltd.
• Pfizer, Inc.
• Rigel Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Sanofi

Market Segmentation

By Disease

• Myeloblastic Leukemia
• Myelomonocytic
• Leukemia
• Promyelocytic Leukemia

By Treatment

• Chemotherapy
• Targeted Therapy
• Immunotherapy

By Route of Administration

• Parenteral
• Oral

By Region

• North America
• Latin America
• Europe
• South Asia & Oceania
• East Asia
• The Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Acute Myeloid Leukemia Treatment Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Epidemiology - Disease Prevalence and Incidence
• 3.2. Technology Assessment
• 3.3. Regulatory Landscape
• 3.4. Value Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Acute Myeloid Leukemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
• 4.3. Global Acute Myeloid Leukemia Treatment Market Outlook: Disease
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Disease, 2019-2023
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
    • 4.3.3.1. Myeloblastic Leukemia
    • 4.3.3.2. Myelomonocytic
    • 4.3.3.3. Leukemia
    • 4.3.3.4. Promyelocytic Leukemia
• 4.4. Market Attractiveness Analysis: Disease
• 4.5. Global Acute Myeloid Leukemia Treatment Market Outlook: Treatment
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Treatment, 2019-2023
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
    • 4.5.3.1. Pharmaceutical companies
    • 4.5.3.2. Biotechnology companies
    • 4.5.3.3. Research institutions
    • 4.5.3.4. Hospitals and clinics
• 4.6. Market Attractiveness Analysis: Treatment
• 4.7. Global Acute Myeloid Leukemia Treatment Market Outlook: Route of Administration
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2023
  • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2031
    • 4.7.3.1. Parenteral
    • 4.7.3.2. Oral
• 4.8. Market Attractiveness Analysis: Route of Administration

5. Global Acute Myeloid Leukemia Treatment Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Acute Myeloid Leukemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 6.2.1. By Country
  • 6.2.2. By Disease
  • 6.2.3. By Treatment
  • 6.2.4. By Route of Administration
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 6.4.1. Myeloblastic Leukemia
  • 6.4.2. Myelomonocytic
  • 6.4.3. Leukemia
  • 6.4.4. Promyelocytic Leukemia
• 6.5. Market Attractiveness Analysis
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 6.6.1. Chemotherapy
  • 6.6.2. Targeted Therapy
  • 6.6.3. Immunotherapy
• 6.7. Market Attractiveness Analysis
• 6.8. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 6.8.1. Parenteral
  • 6.8.2. Oral
• 6.9. Market Attractiveness Analysis

7. Europe Acute Myeloid Leukemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 7.2.1. By Country
  • 7.2.2. By Disease
  • 7.2.3. By Treatment
  • 7.2.4. By Route of Administration
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkiye
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 7.4.1. Myeloblastic Leukemia
  • 7.4.2. Myelomonocytic
  • 7.4.3. Leukemia
  • 7.4.4. Promyelocytic Leukemia
• 7.5. Market Attractiveness Analysis
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 7.6.1. Chemotherapy
  • 7.6.2. Targeted Therapy
  • 7.6.3. Immunotherapy
• 7.7. Market Attractiveness Analysis
• 7.8. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 7.8.1. Parenteral
  • 7.8.2. Oral
• 7.9. Market Attractiveness Analysis

8. East Asia Acute Myeloid Leukemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 8.2.1. By Country
  • 8.2.2. By Disease
  • 8.2.3. By Treatment
  • 8.2.4. By Route of Administration
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 8.4.1. Myeloblastic Leukemia
  • 8.4.2. Myelomonocytic
  • 8.4.3. Leukemia
  • 8.4.4. Promyelocytic Leukemia
• 8.5. Market Attractiveness Analysis
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 8.6.1. Chemotherapy
  • 8.6.2. Targeted Therapy
  • 8.6.3. Immunotherapy
• 8.7. Market Attractiveness Analysis
• 8.8. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 8.8.1. Parenteral
  • 8.8.2. Oral
• 8.9. Market Attractiveness Analysis

9. South Asia & Oceania Acute Myeloid Leukemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 9.2.1. By Country
  • 9.2.2. By Disease
  • 9.2.3. By Treatment
  • 9.2.4. By Route of Administration
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 9.4.1. Myeloblastic Leukemia
  • 9.4.2. Myelomonocytic
  • 9.4.3. Leukemia
  • 9.4.4. Promyelocytic Leukemia
• 9.5. Market Attractiveness Analysis
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 9.6.1. Chemotherapy
  • 9.6.2. Targeted Therapy
  • 9.6.3. Immunotherapy
• 9.7. Market Attractiveness Analysis
• 9.8. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 9.8.1. Parenteral
  • 9.8.2. Oral
• 9.9. Market Attractiveness Analysis

10. Latin America Acute Myeloid Leukemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 10.2.1. By Country
  • 10.2.2. By Disease
  • 10.2.3. By Treatment
  • 10.2.4. By Route of Administration
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 10.3.1. Myeloblastic Leukemia
  • 10.3.2. Myelomonocytic
  • 10.3.3. Leukemia
  • 10.3.4. Promyelocytic Leukemia
• 10.4. Market Attractiveness Analysis
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 10.5.1. Chemotherapy
  • 10.5.2. Targeted Therapy
  • 10.5.3. Immunotherapy
• 10.6. Market Attractiveness Analysis
• 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 10.7.1. Parenteral
  • 10.7.2. Oral
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Acute Myeloid Leukemia Treatment Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 11.2.1. By Country
  • 11.2.2. By Disease
  • 11.2.3. By Treatment
  • 11.2.4. By Route of Administration
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease, 2024-2031
  • 11.4.1. Myeloblastic Leukemia
  • 11.4.2. Myelomonocytic
  • 11.4.3. Leukemia
  • 11.4.4. Promyelocytic Leukemia
• 11.5. Market Attractiveness Analysis
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
  • 11.6.1. Chemotherapy
  • 11.6.2. Targeted Therapy
  • 11.6.3. Immunotherapy
• 11.7. Market Attractiveness Analysis
• 11.8. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2031
  • 11.8.1. Parenteral
  • 11.8.2. Oral
• 11.9. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Astellas Pharma Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Bristol Myers Squibb Company
  • 12.3.3. Celgene Corporation
  • 12.3.4. Daiichi Sankyo Company, Limited
  • 12.3.5. Jazz Pharmaceuticals, plc
  • 12.3.6. Novartis AG
  • 12.3.7. Otsuka Pharmaceuticals Co., Ltd.
  • 12.3.8. Pfizer, Inc.
  • 12.3.9. Rigel Pharmaceuticals, Inc.
  • 12.3.10. Merck & Co., Inc.
  • 12.3.11. Sanofi

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations